- The evaluation produced six-monthly monitoring and value for money reports for DFID Myanmar. In addition, a series of publishable papers have been produced on a number of strategic issues. These papers cover the following topics:
-
- Lessons learnt on incentivising the distribution and use of Rapid Diagnostic Tests for the diagnosis of malaria by private sector providers
- The role of the private pharmaceutical sector in containing drug resistance in Myanmar
- The impact of AMTR in containing drug resistance
- A study into the treatment seeking behaviour of customers/patients within Myanmar
- A sensitivity analysis of the calculation of Disability Adjusted Life Years (DALYs) in the context of AMTR
- A consideration of options for adding Primaquine to the standard treatment guidelines for uncomplicated falciparum malaria in Myanmar
- A qualitative analysis of the decision making processes amongst migrant worker populations in Myanmar regarding the use of private or public sector health providers
- An examination of the role of the broader Myanmar corporate sector in contributing to the spread or containment of drug resistance
- Five of these papers were launched at a major meeting of stakeholders which included government, development agencies, NGOs, researchers, corporate sector, private providers and civil society on 1 April 2015 in Yangon. They can be found here:
Myanmar AMTR Independent Evaluation – Working Paper 1 – DALYs – v2
Myanmar AMTR Independent Evaluation – Working Paper 2 – Primaquine – v2
Myanmar AMTR Independent Evaluation – Working Paper 3 – Migratory Worker…
Myanmar AMTR Independent Evaluation – Working Paper 4 – Corporate Role -…
Myanmar AMTR Independent Evaluation – Case Study 2 – Private Providers -…